AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
liothyronine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1585 | 6893-02-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mcg | O |
| 60 | mcg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.597 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 11.858 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 5.082 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.426 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.550 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.780 | % | High | 1 |
| herg | hERG pIC50 | 4.932 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 6.138 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 6.067 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.650 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K1,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 73 | |||
| kinase-selectivity-class | ACVR2B,AURKA,AURKC,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT4,GRK2,GSK3A,GSK3B,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP4K1,MAPK1,MAPK7,PIK3CB,PIK3CD,PRKDC,SIK2,STK10,STK33,SYK,TEK,TGFBR1,TTK | 35 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 18.197 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 15.524 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.400 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 13.122 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.710 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 19.275 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 13.930 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.340 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 5.470 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 8, 1956 | FDA | KING PHARMS R AND D |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sensitisation | 550.39 | 15.13 | 133 | 16975 | 4042 | 90607297 |
| Polycystic ovaries | 520.01 | 15.13 | 135 | 16973 | 5519 | 90605820 |
| Ejection fraction | 443.87 | 15.13 | 105 | 17003 | 2906 | 90608433 |
| Rhinitis allergic | 378.96 | 15.13 | 136 | 16972 | 16649 | 90594690 |
| Carpal tunnel syndrome | 356.15 | 15.13 | 143 | 16965 | 23785 | 90587554 |
| Blood test abnormal | 353.14 | 15.13 | 137 | 16971 | 20815 | 90590524 |
| Hypothyroidism | 344.84 | 15.13 | 178 | 16930 | 52949 | 90558390 |
| Sleep apnoea syndrome | 339.61 | 15.13 | 150 | 16958 | 31597 | 90579742 |
| Burning sensation | 267.36 | 15.13 | 160 | 16948 | 63292 | 90548047 |
| Renal disorder | 254.70 | 15.13 | 130 | 16978 | 37729 | 90573610 |
| Sleep disorder due to a general medical condition | 250.87 | 15.13 | 136 | 16972 | 44602 | 90566737 |
| Cardiac disorder | 248.96 | 15.13 | 147 | 16961 | 56725 | 90554614 |
| Ejection fraction abnormal | 231.51 | 15.13 | 60 | 17048 | 2431 | 90608908 |
| Nephrectomy | 195.23 | 15.13 | 50 | 17058 | 1931 | 90609408 |
| Gastrooesophageal reflux disease | 142.35 | 15.13 | 166 | 16942 | 166171 | 90445168 |
| Loss of personal independence in daily activities | 123.44 | 15.13 | 140 | 16968 | 135965 | 90475374 |
| Asthma | 121.32 | 15.13 | 186 | 16922 | 241974 | 90369365 |
| Therapeutic product effect incomplete | 113.06 | 15.13 | 160 | 16948 | 193736 | 90417603 |
| Fibromyalgia | 95.70 | 15.13 | 153 | 16955 | 206116 | 90405223 |
| Headache | 82.44 | 15.13 | 351 | 16757 | 862395 | 89748944 |
| Choroidal effusion | 78.16 | 15.13 | 20 | 17088 | 769 | 90610570 |
| Full blood count abnormal | 76.69 | 15.13 | 60 | 17048 | 36537 | 90574802 |
| Nephropathy | 59.99 | 15.13 | 31 | 17077 | 9204 | 90602135 |
| Hypertension | 59.86 | 15.13 | 206 | 16902 | 457326 | 90154013 |
| Hyperthyroidism | 54.21 | 15.13 | 37 | 17071 | 18273 | 90593066 |
| Angle closure glaucoma | 49.76 | 15.13 | 19 | 17089 | 2756 | 90608583 |
| Glossodynia | 48.82 | 15.13 | 3 | 17105 | 321776 | 90289563 |
| Arthropathy | 48.59 | 15.13 | 6 | 17102 | 366236 | 90245103 |
| Systemic lupus erythematosus | 43.26 | 15.13 | 8 | 17100 | 361888 | 90249451 |
| Suicidal ideation | 43.04 | 15.13 | 61 | 17047 | 73794 | 90537545 |
| Urine chloride decreased | 40.82 | 15.13 | 8 | 17100 | 87 | 90611252 |
| Drug intolerance | 40.37 | 15.13 | 17 | 17091 | 447574 | 90163765 |
| Treatment failure | 40.25 | 15.13 | 5 | 17103 | 303923 | 90307416 |
| Wound | 40.09 | 15.13 | 5 | 17103 | 302975 | 90308364 |
| Maternal exposure during pregnancy | 38.90 | 15.13 | 10 | 17098 | 360053 | 90251286 |
| Hospitalisation | 38.79 | 15.13 | 79 | 17029 | 128021 | 90483318 |
| Thyroid function test abnormal | 36.75 | 15.13 | 17 | 17091 | 3972 | 90607367 |
| Wheezing | 36.27 | 15.13 | 113 | 16995 | 237967 | 90373372 |
| Urine sodium decreased | 36.18 | 15.13 | 8 | 17100 | 162 | 90611177 |
| Palpitations | 34.15 | 15.13 | 78 | 17030 | 136650 | 90474689 |
| Product substitution issue | 32.37 | 15.13 | 27 | 17081 | 17981 | 90593358 |
| Feeling abnormal | 31.84 | 15.13 | 86 | 17022 | 167149 | 90444190 |
| Product dose omission issue | 31.06 | 15.13 | 123 | 16985 | 291564 | 90319775 |
| Myopathy | 30.13 | 15.13 | 23 | 17085 | 13495 | 90597844 |
| General physical health deterioration | 29.66 | 15.13 | 15 | 17093 | 355100 | 90256239 |
| Type 2 diabetes mellitus | 27.76 | 15.13 | 3 | 17105 | 203241 | 90408098 |
| Hepatic enzyme increased | 27.58 | 15.13 | 17 | 17091 | 360719 | 90250620 |
| Acute kidney injury | 26.06 | 15.13 | 14 | 17094 | 320373 | 90290966 |
| Lower respiratory tract infection | 25.14 | 15.13 | 8 | 17100 | 250651 | 90360688 |
| Pre-existing condition improved | 23.58 | 15.13 | 17 | 17091 | 9152 | 90602187 |
| Scar | 23.45 | 15.13 | 21 | 17087 | 15374 | 90595965 |
| Product administration interrupted | 23.01 | 15.13 | 19 | 17089 | 12473 | 90598866 |
| Blood thyroid stimulating hormone decreased | 22.91 | 15.13 | 14 | 17094 | 5726 | 90605613 |
| Infusion related reaction | 21.82 | 15.13 | 28 | 17080 | 416752 | 90194587 |
| Impaired healing | 20.92 | 15.13 | 9 | 17099 | 234190 | 90377149 |
| Joint swelling | 20.49 | 15.13 | 40 | 17068 | 503260 | 90108079 |
| Myxoedema coma | 20.15 | 15.13 | 6 | 17102 | 406 | 90610933 |
| Lichen sclerosus | 19.76 | 15.13 | 8 | 17100 | 1355 | 90609984 |
| Illness | 19.62 | 15.13 | 46 | 17062 | 81923 | 90529416 |
| Vision blurred | 19.28 | 15.13 | 55 | 17053 | 110238 | 90501101 |
| Tri-iodothyronine decreased | 18.59 | 15.13 | 5 | 17103 | 234 | 90611105 |
| Blood thyroid stimulating hormone abnormal | 18.32 | 15.13 | 7 | 17101 | 1017 | 90610322 |
| Nail growth abnormal | 17.91 | 15.13 | 6 | 17102 | 596 | 90610743 |
| Peak expiratory flow rate decreased | 17.54 | 15.13 | 6 | 17102 | 636 | 90610703 |
| Dyspnoea | 17.21 | 15.13 | 247 | 16861 | 880708 | 89730631 |
| Thrombocytopenia | 17.14 | 15.13 | 9 | 17099 | 208716 | 90402623 |
| Blood thyroid stimulating hormone increased | 17.02 | 15.13 | 14 | 17094 | 9141 | 90602198 |
| Anxiety | 16.81 | 15.13 | 108 | 17000 | 309664 | 90301675 |
| Vascular parkinsonism | 16.49 | 15.13 | 4 | 17104 | 123 | 90611216 |
| Toxicity to various agents | 16.49 | 15.13 | 18 | 17090 | 287828 | 90323511 |
| Blister | 15.68 | 15.13 | 15 | 17093 | 254983 | 90356356 |
| Myalgia | 15.61 | 15.13 | 70 | 17038 | 175055 | 90436284 |
| Eye irritation | 15.43 | 15.13 | 25 | 17083 | 33953 | 90577386 |
| Strabismus | 15.21 | 15.13 | 8 | 17100 | 2460 | 90608879 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperthyroidism | 73.46 | 24.33 | 29 | 2580 | 14312 | 42604414 |
| Loose associations | 52.27 | 24.33 | 8 | 2601 | 62 | 42618664 |
| Cardiac valve fibroelastoma | 47.44 | 24.33 | 7 | 2602 | 41 | 42618685 |
| Rhythm idioventricular | 45.32 | 24.33 | 9 | 2600 | 344 | 42618382 |
| Intentional product misuse | 44.57 | 24.33 | 34 | 2575 | 61866 | 42556860 |
| Diffuse vasculitis | 42.89 | 24.33 | 7 | 2602 | 85 | 42618641 |
| Feelings of worthlessness | 40.03 | 24.33 | 8 | 2601 | 316 | 42618410 |
| Secondary hypogonadism | 38.15 | 24.33 | 9 | 2600 | 777 | 42617949 |
| Thyrotoxic periodic paralysis | 37.82 | 24.33 | 7 | 2602 | 183 | 42618543 |
| Glucose tolerance decreased | 36.83 | 24.33 | 6 | 2603 | 72 | 42618654 |
| Autoimmune thyroiditis | 36.49 | 24.33 | 10 | 2599 | 1572 | 42617154 |
| Pressure of speech | 35.54 | 24.33 | 8 | 2601 | 561 | 42618165 |
| Blood thyroid stimulating hormone decreased | 32.69 | 24.33 | 10 | 2599 | 2313 | 42616413 |
| Performance enhancing product use | 32.45 | 24.33 | 6 | 2603 | 156 | 42618570 |
| Subcutaneous emphysema | 31.21 | 24.33 | 9 | 2600 | 1700 | 42617026 |
| Perforation | 30.98 | 24.33 | 7 | 2602 | 499 | 42618227 |
| Sinus arrest | 29.15 | 24.33 | 9 | 2600 | 2147 | 42616579 |
| Hypothalamic pituitary adrenal axis suppression | 28.70 | 24.33 | 6 | 2603 | 297 | 42618429 |
| Insomnia | 27.54 | 24.33 | 35 | 2574 | 118218 | 42500508 |
| Cardiac failure acute | 26.35 | 24.33 | 14 | 2595 | 13619 | 42605107 |
| Myocarditis | 24.60 | 24.33 | 15 | 2594 | 18923 | 42599803 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sensitisation | 527.69 | 15.44 | 122 | 15834 | 4029 | 110569314 |
| Polycystic ovaries | 520.54 | 15.44 | 124 | 15832 | 4672 | 110568671 |
| Ejection fraction | 419.31 | 15.44 | 95 | 15861 | 2860 | 110570483 |
| Carpal tunnel syndrome | 360.24 | 15.44 | 132 | 15824 | 22478 | 110550865 |
| Rhinitis allergic | 358.96 | 15.44 | 124 | 15832 | 17798 | 110555545 |
| Blood test abnormal | 302.73 | 15.44 | 124 | 15832 | 28430 | 110544913 |
| Hypothyroidism | 289.49 | 15.44 | 161 | 15795 | 72738 | 110500605 |
| Sleep apnoea syndrome | 282.89 | 15.44 | 131 | 15825 | 40316 | 110533027 |
| Burning sensation | 253.51 | 15.44 | 145 | 15811 | 69067 | 110504276 |
| Sleep disorder due to a general medical condition | 231.50 | 15.44 | 124 | 15832 | 51988 | 110521355 |
| Renal disorder | 223.35 | 15.44 | 119 | 15837 | 49360 | 110523983 |
| Ejection fraction abnormal | 218.40 | 15.44 | 58 | 15898 | 3402 | 110569941 |
| Cardiac disorder | 212.40 | 15.44 | 134 | 15822 | 76146 | 110497197 |
| Nephrectomy | 189.45 | 15.44 | 49 | 15907 | 2591 | 110570752 |
| Gastrooesophageal reflux disease | 143.06 | 15.44 | 152 | 15804 | 179824 | 110393519 |
| Fibromyalgia | 128.19 | 15.44 | 140 | 15816 | 170769 | 110402574 |
| Hyperthyroidism | 117.06 | 15.44 | 65 | 15891 | 29196 | 110544147 |
| Asthma | 114.76 | 15.44 | 160 | 15796 | 250131 | 110323212 |
| Loss of personal independence in daily activities | 110.93 | 15.44 | 122 | 15834 | 149898 | 110423445 |
| Therapeutic product effect incomplete | 102.47 | 15.44 | 143 | 15813 | 223662 | 110349681 |
| Headache | 88.02 | 15.44 | 303 | 15653 | 882074 | 109691269 |
| Hypertension | 68.09 | 15.44 | 194 | 15762 | 509890 | 110063453 |
| Nephropathy | 56.83 | 15.44 | 31 | 15925 | 13436 | 110559907 |
| Full blood count abnormal | 45.62 | 15.44 | 48 | 15908 | 56004 | 110517339 |
| Blood thyroid stimulating hormone decreased | 43.08 | 15.44 | 21 | 15935 | 7218 | 110566125 |
| Loose associations | 43.06 | 15.44 | 8 | 15948 | 86 | 110573257 |
| Urine chloride decreased | 41.87 | 15.44 | 8 | 15948 | 101 | 110573242 |
| Cardiac valve fibroelastoma | 40.11 | 15.44 | 7 | 15949 | 51 | 110573292 |
| Wheezing | 38.88 | 15.44 | 102 | 15854 | 255128 | 110318215 |
| Hospitalisation | 36.40 | 15.44 | 70 | 15886 | 142423 | 110430920 |
| Diffuse vasculitis | 34.75 | 15.44 | 7 | 15949 | 118 | 110573225 |
| Urine sodium decreased | 34.38 | 15.44 | 8 | 15948 | 271 | 110573072 |
| Suicidal ideation | 31.52 | 15.44 | 52 | 15904 | 93885 | 110479458 |
| Glucose tolerance decreased | 31.46 | 15.44 | 6 | 15950 | 75 | 110573268 |
| Feeling abnormal | 31.46 | 15.44 | 76 | 15880 | 180635 | 110392708 |
| Insulin-like growth factor increased | 31.41 | 15.44 | 12 | 15944 | 2284 | 110571059 |
| Thyrotoxic periodic paralysis | 31.26 | 15.44 | 7 | 15949 | 199 | 110573144 |
| Rhythm idioventricular | 30.49 | 15.44 | 9 | 15947 | 776 | 110572567 |
| Secondary hypogonadism | 29.65 | 15.44 | 9 | 15947 | 854 | 110572489 |
| Feelings of worthlessness | 28.43 | 15.44 | 8 | 15948 | 582 | 110572761 |
| Product dose omission issue | 28.05 | 15.44 | 106 | 15850 | 321676 | 110251667 |
| Myxoedema coma | 27.06 | 15.44 | 8 | 15948 | 694 | 110572649 |
| Performance enhancing product use | 26.92 | 15.44 | 6 | 15950 | 167 | 110573176 |
| Synovitis | 26.42 | 15.44 | 4 | 15952 | 274088 | 110299255 |
| Acute kidney injury | 26.11 | 15.44 | 32 | 15924 | 635398 | 109937945 |
| Arthropathy | 25.95 | 15.44 | 5 | 15951 | 287517 | 110285826 |
| Thrombocytopenia | 25.90 | 15.44 | 9 | 15947 | 348876 | 110224467 |
| General physical health deterioration | 25.30 | 15.44 | 15 | 15941 | 425280 | 110148063 |
| Myopathy | 25.14 | 15.44 | 24 | 15932 | 24936 | 110548407 |
| Thyroid function test abnormal | 23.81 | 15.44 | 11 | 15945 | 3356 | 110569987 |
| Subcutaneous emphysema | 23.27 | 15.44 | 10 | 15946 | 2574 | 110570769 |
| Lichen sclerosus | 23.05 | 15.44 | 8 | 15948 | 1160 | 110572183 |
| Palpitations | 22.58 | 15.44 | 62 | 15894 | 159150 | 110414193 |
| Tri-iodothyronine increased | 22.34 | 15.44 | 6 | 15950 | 367 | 110572976 |
| Product administration interrupted | 22.19 | 15.44 | 16 | 15940 | 11276 | 110562067 |
| Intentional product misuse | 22.17 | 15.44 | 55 | 15901 | 132849 | 110440494 |
| Pyrexia | 22.03 | 15.44 | 62 | 15894 | 898203 | 109675140 |
| Pressure of speech | 22.02 | 15.44 | 8 | 15948 | 1324 | 110572019 |
| Product substitution issue | 21.03 | 15.44 | 21 | 15935 | 23040 | 110550303 |
| Scar | 20.45 | 15.44 | 18 | 15938 | 16863 | 110556480 |
| Tracheal injury | 19.96 | 15.44 | 5 | 15951 | 232 | 110573111 |
| Systemic lupus erythematosus | 19.86 | 15.44 | 6 | 15950 | 254332 | 110319011 |
| Drug interaction | 19.69 | 15.44 | 26 | 15930 | 500157 | 110073186 |
| Autoimmune thyroiditis | 19.64 | 15.44 | 12 | 15944 | 6422 | 110566921 |
| Anaemia | 19.03 | 15.44 | 31 | 15925 | 547055 | 110026288 |
| Toxicity to various agents | 18.90 | 15.44 | 25 | 15931 | 480530 | 110092813 |
| Hypothalamic pituitary adrenal axis suppression | 18.76 | 15.44 | 6 | 15950 | 676 | 110572667 |
| Peak expiratory flow rate decreased | 18.61 | 15.44 | 6 | 15950 | 694 | 110572649 |
| Drug withdrawal syndrome | 18.40 | 15.44 | 25 | 15931 | 38029 | 110535314 |
| Adverse event | 18.11 | 15.44 | 45 | 15911 | 108764 | 110464579 |
| Febrile neutropenia | 17.69 | 15.44 | 12 | 15944 | 316755 | 110256588 |
| Vascular parkinsonism | 17.66 | 15.44 | 4 | 15952 | 120 | 110573223 |
| Wound | 17.47 | 15.44 | 6 | 15950 | 234431 | 110338912 |
| Pericarditis | 17.42 | 15.44 | 5 | 15951 | 219109 | 110354234 |
| Breast pain | 17.03 | 15.44 | 13 | 15943 | 9987 | 110563356 |
| Hepatic enzyme increased | 16.82 | 15.44 | 13 | 15943 | 320879 | 110252464 |
| Perforation | 16.28 | 15.44 | 7 | 15949 | 1803 | 110571540 |
| Treatment failure | 16.17 | 15.44 | 10 | 15946 | 277224 | 110296119 |
| Nail growth abnormal | 15.84 | 15.44 | 5 | 15951 | 540 | 110572803 |
| Sinus arrest | 15.81 | 15.44 | 9 | 15947 | 4233 | 110569110 |
| Anxiety | 15.59 | 15.44 | 94 | 15862 | 344984 | 110228359 |
| Blood follicle stimulating hormone decreased | 15.56 | 15.44 | 4 | 15952 | 206 | 110573137 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H03AA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
| ATC | H03AA03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones |
| FDA CS | M0021977 | Triiodothyronine |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| FDA EPC | N0000175946 | l-Triiodothyronine |
Related Drugs by ATC class:
H03AA Thyroid hormones 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Goiter | indication | 3716002 | DOID:12176 |
| Myxedema coma | indication | 21263006 | |
| Hypothyroidism | indication | 40930008 | DOID:1459 |
| Myxedema | indication | 43153006 | DOID:11634 |
| Congenital hypothyroidism | indication | 190268003 | DOID:0050328 |
| Simple goiter | indication | 267369002 | |
| Malignant tumor of thyroid gland | indication | 363478007 | DOID:1781 |
| T3 Suppression for Thyroid Function Test | indication | ||
| Mild Hypothyroidism | indication | ||
| Diagnostic Test for Thyroid Dysfunction | indication | ||
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Thyrotoxic crisis | contraindication | 29028009 | DOID:12837 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Osteoporosis | contraindication | 64859006 | DOID:11476 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hypopituitarism | contraindication | 74728003 | DOID:9406 |
| Angina pectoris | contraindication | 194828000 | |
| Osteopenia | contraindication | 312894000 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Disorder of coronary artery | contraindication | 414024009 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Hypothyroidism | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Cytobin Tablets | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.08 | acidic |
| pKa2 | 8.12 | acidic |
| pKa3 | 8.77 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid hormone receptor alpha | Nuclear hormone receptor | AGONIST | Kd | 10.24 | CHEMBL | CHEMBL | |||
| Thyroid hormone receptor beta | Nuclear hormone receptor | AGONIST | Ki | 10.10 | CHEMBL | CHEMBL | |||
| Adenosine receptor A1 | GPCR | Ki | 6.62 | DRUG MATRIX | |||||
| Cytochrome P450 2C9 | Enzyme | EC50 | 6.30 | WOMBAT-PK | |||||
| Prothrombin | Enzyme | EC50 | 8.92 | CHEMBL | |||||
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | Kd | 6.15 | CHEMBL | |||||
| Proliferating cell nuclear antigen | Nuclear other | IC50 | 5.44 | CHEMBL | |||||
| THAP domain-containing protein 1 | Transcription factor | EC50 | 9 | WOMBAT-PK | |||||
| GABA-A receptor; anion channel | Ion channel | IC50 | 4.64 | CHEMBL | |||||
| Thyroid hormone receptor beta | Transcription factor | IC50 | 8.74 | CHEMBL | |||||
| GABA-A receptor; anion channel | Ion channel | EC50 | 5.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4022167 | VUID |
| N0000020173 | NUI |
| D01011 | KEGG_DRUG |
| 55-06-1 | SECONDARY_CAS_RN |
| 4018002 | VANDF |
| 4022167 | VANDF |
| C0041014 | UMLSCUI |
| CHEBI:18258 | CHEBI |
| T3 | PDB_CHEM_ID |
| CHEMBL1544 | ChEMBL_ID |
| CHEMBL1201119 | ChEMBL_ID |
| D014284 | MESH_DESCRIPTOR_UI |
| DB00279 | DRUGBANK_ID |
| 653 | INN_ID |
| 06LU7C9H1V | UNII |
| 5920 | PUBCHEM_CID |
| 10814 | RXNORM |
| 1964 | MMSL |
| 4982 | MMSL |
| d00658 | MMSL |
| 002133 | NDDF |
| 004882 | NDDF |
| 126204001 | SNOMEDCT_US |
| 350358003 | SNOMEDCT_US |
| 61275002 | SNOMEDCT_US |
| 2634 | IUPHAR_LIGAND_ID |
| 06LU7C9H1V | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2178 | TABLET | 25 ug | ORAL | ANDA | 26 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2179 | TABLET | 5 ug | ORAL | ANDA | 26 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2180 | TABLET | 50 ug | ORAL | ANDA | 26 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-303 | TABLET | 50 1 | ORAL | ANDA | 13 sections |
| Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-166 | TABLET | 5 ug | ORAL | ANDA | 24 sections |
| Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-167 | TABLET | 25 ug | ORAL | ANDA | 24 sections |
| Liothyronine sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-168 | TABLET | 50 ug | ORAL | ANDA | 24 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-502 | TABLET | 4.50 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-502 | TABLET | 4.50 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-502 | TABLET | 4.50 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-503 | TABLET | 9 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-503 | TABLET | 9 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-503 | TABLET | 9 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-504 | TABLET | 13.50 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-504 | TABLET | 13.50 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-504 | TABLET | 13.50 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-505 | TABLET | 18 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-505 | TABLET | 18 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-505 | TABLET | 18 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-511 | TABLET | 2.25 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-511 | TABLET | 2.25 ug | ORAL | unapproved drug other | 8 sections |
| NP Thyroid | HUMAN OTC DRUG LABEL | 2 | 17224-511 | TABLET | 2.25 ug | ORAL | unapproved drug other | 8 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-964 | TABLET | 5 ug | ORAL | ANDA | 25 sections |
| Liothyronine Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0151 | INJECTION, SOLUTION | 10 ug | INTRAVENOUS | ANDA | 25 sections |
| NP Thyroid 15 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-327 | TABLET | 2.25 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 120 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-328 | TABLET | 18 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-329 | TABLET | 4.50 ug | ORAL | unapproved drug other | 23 sections |
| NP Thyroid 60 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42192-330 | TABLET | 9 ug | ORAL | unapproved drug other | 22 sections |